NCT07763834Not yet recruiting
Uromodulin as a Biomarker in Lupus Nephritis
Evaluation of Uromodulin as a Biomarker of Renal Histological Activity/ Chronicity Indices in Lupus Nephritis
Source: ClinicalTrials.gov · Last updated 13 Aug 2026
Brief summary (registry, in English)
Evaluation of Uromodulin as a biomarker of renal histological activity/ Chronicity indices in lupus nephritis
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 90 (estimated)
- First submitted
- 9 Aug 2026
- Start date
- 1 Oct 2026
- Primary completion date
- 2 Aug 2029
- Lead sponsor
- Assiut University
- Diseases
- Lupus (SLE)
- NCT number
- NCT07763834
What you commit to
- Study type: Observational
- Planned participants: 90
- From 1 Oct 2026 to the primary completion date, 2 Aug 2029
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- • Group I: 30 patients with different classes of Lupus Nephritis. These cases are biopsy proven
- LN. Histological diagnosis of LN is according to the revised International Society of
- Nephrology/ Renal Pathology Society (ISN/RPS) classification and modified National Institute of Health (NIH) activity and chronicity indices (Bajema et al 2018) .
- Biopsy-proven lupus nephritis at the time of uromodulin blood sampling.
- Group II: 10 patients with active SLE without renal involvement and with SLEDAI score ≥6
- Group III: 10 patients with non-active SLE with SLEDAI score \<6
- Group IV: 30 patients with primary forms of non-lupus Glomerulonephritis
- Group V: 10 healthy control subjects
- All cases are adults ≥18 years.
- Diagnosis of systemic lupus erythematosus according to the 2019 EULAR/ACR Classification
- Criteria (Ref).Exclusion Criteria:
- • .Pregnancy or lactation
- AKI secondary to pre renal OR post renal cause (from clinical history and imaging).
- End-stage renal disease requiring dialysis
- Active infection or sepsis
- Active malignancy (either under treatment or within 5 years of successful treatment)
- History of renal transplantation
- Heart failure with NYHA III and IV
- Hhistory of other autoimmune diseases or diabetes mellitus
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.